IDEXX Laboratories Shares Climb Past $700 Following Strong Third-Quarter Results
IDEXX Laboratories stock surged past $700 after beating third-quarter forecasts and raising its full-year outlook, though valuation concerns and recent insider sales have emerged.
Shares of IDEXX Laboratories, Inc. (IDXX) recently extended their upward momentum, rising 4.5% on November 09, 2026, to reach $706.65. That movement sits within a 52-week trading range of $500.61 to $769.98. The recent climb follows a sharp rally on November 2, 2026, when the stock surged by more than 21% after the company released third-quarter financial results that exceeded market expectations.
The quarterly surprise was powered by operations across IDEXX's pet business. The Companion Animal Group accounted for $3.95 billion of the company's total $4.3 billion revenue in fiscal 2025. In the recent period, recurring diagnostics revenue expanded by about one-ninth, fueled by in-clinic analyzer consumables growing at a mid-teens organic rate. However, rapid assay product volumes were lower, offset by price increases, and capital instrument revenue finished flat despite customer placements of newer inVue Dx analyzers. Full-year revenue and earnings per share targets were raised, though the operating margin range was lowered due to acquisition costs and commercial capital investments.
Robust cash generation continues to fund capital returns and strategic expansion. Over the past four quarters, IDEXX produced $1.3 billion of free cash flow and spent $1.05 billion repurchasing shares. Consistent share retirements lowered the company's diluted share count from 84.0 million to 79.0 million over three years, helping earnings per share outpace net income growth. IDEXX paid no dividend and lowered its total debt to $0.973 billion by the end of September 2026, down from $1.11 billion a year earlier. Operating cash was also deployed to fund the acquisition of CoVet, an artificial intelligence clinical assistant designed for veterinary teams.
Wall Street firms adjusted their views in response to the third-quarter report and shifting industry dynamics. Goldman Sachs initiated coverage with a Buy rating and a $740 price target. JPMorgan trimmed its target to $750 from $775 but retained an Overweight rating. In contrast, KeyBanc began coverage with a Sector Weight stance, citing concerns over soft trends in U.S. veterinary clinic visits. Jefferies reduced its target to $705 from $795, and UBS decreased its target to $627 from $670 while maintaining a Neutral rating.
Valuation metrics and insider activity have drawn attention following the stock's run. A GuruFocus analysis estimated the company's intrinsic fair value at $644.87, labeling the $706.65 share price as 9.6% overvalued, with a price-to-earnings ratio of 47.6x compared to a 5-year median of 48.8x. GuruFocus also reported that company insiders sold $58.4 million in stock over the past 12 months with no recorded insider purchases.